EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap

Anneliene H Jonker, Elena-Alexandra Tataru, Holm Graessner, David Dimmock, Adam Jaffe, Gareth Baynam, James Davies, Shruti Mitkus, Oxana Iliach, Rich Horgan, Erika F Augustine, Alison Bateman-House und 9 weitere

Nature Reviews Drug Discovery · 2025

DOI: 10.1038/s41573-024-01059-3 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nature Reviews Drug Discovery, 2025. Verfasst von Anneliene H Jonker und 20 weiteren Autor:innen. Beteiligte Einrichtung: HTSR, TechMed Centre, University of Twente, Enschede, The Netherlands. Hauptthemen laut MEDLINE: Drug Development, Genetic Therapy, Precision Medicine, Single-Case Studies as Topic. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 131 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In recent years, a small number of people with rare diseases caused by unique genetic variants have been treated with therapies developed specifically for them. This pioneering field of genetic N-of-1 therapies is evolving rapidly, giving hope for the individualized treatment of people living with very rare diseases. In this Review, we outline the concept of N-of-1 individualized therapies, focusing on genetic therapies, and illustrate advances and challenges in the field using cases for which therapies have been successfully developed. We discuss why the traditional drug development and reimbursement pathway is not fit for purpose in this field, and outline the pragmatic, regulatory and ethical challenges this poses for future access to N-of-1 therapies. Finally, we provide a roadmap for N-of-1 individualized therapy development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DevelopmentGenetic TherapyPrecision MedicineSingle-Case Studies as TopicHumansRare Diseases

Autor:innen und Institutionen

  • HTSR, TechMed Centre, University of Twente, Enschede, The Netherlands.
  • French National Institute of Health and Medical Research (INSERM), Paris, France.
  • International Rare Diseases Research Consortium (IRDiRC), Paris, France.
  • Centre for Rare Diseases, University Hospital Tübingen, Tübingen, Germany.
  • Creyon Bio, San Diego, CA, USA.
  • School of Clinical Medicine, University of New South Wales, Faculty of Medicine, Sydney, New South Wales, Australia.

Zitieren

APA

Jonker, A. H., Tataru, E. A., Graessner, H., Dimmock, D., Jaffe, A., Baynam, G., Davies, J., Mitkus, S., Iliach, O., Horgan, R., Augustine, E. F., Bateman-House, A., Pasmooij, A. M. G., Yu, T., Synofzik, M., Douville, J., Lapteva, L., Brooks, P. J., O'Connor, D., …, & N-of-1 Task Force of the International Rare Diseases Research Consortium (IRDiRC) (2025). The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap. Nature Reviews Drug Discovery. https://doi.org/10.1038/s41573-024-01059-3

Vancouver

Jonker AH, Tataru EA, Graessner H, Dimmock D, Jaffe A, Baynam G, et al. The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap. Nature Reviews Drug Discovery. 2025. doi:10.1038/s41573-024-01059-3

BibTeX
@article{Jonker2025,
  author = {Jonker, Anneliene H and Tataru, Elena-Alexandra and Graessner, Holm and Dimmock, David and Jaffe, Adam and Baynam, Gareth and Davies, James and Mitkus, Shruti and Iliach, Oxana and Horgan, Rich and Augustine, Erika F and Bateman-House, Alison and Pasmooij, Anna Maria Gerdina and Yu, Tim and Synofzik, Matthis and Douville, Julie and Lapteva, Larissa and Brooks, Philip John and O'Connor, Daniel and Aartsma-Rus, Annemieke and N-of-1 Task Force of the International Rare Diseases Research Consortium (IRDiRC), N-of-1 Task Force of the International Rare Diseases Research Consortium (IRDiRC)},
  title = {The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap},
  journal = {Nature Reviews Drug Discovery},
  year = {2025},
  doi = {10.1038/s41573-024-01059-3}
}
Kostenlos starten →